- Home
- CLVT vs RNA Comparison
CLVT vs RNA Comparison
Compare CLVT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLVT
- RNA
- Stock Information
- Founded
- CLVT 2016
- RNA 2012
- Country
- CLVT United Kingdom
- RNA United States
- Employees
- CLVT N/A
- RNA N/A
- Industry
- CLVT EDP Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- CLVT Technology
- RNA Health Care
- Exchange
- CLVT Nasdaq
- RNA Nasdaq
- Market Cap
- CLVT 3.6B
- RNA 3.7B
- IPO Year
- CLVT N/A
- RNA 2020
- Fundamental
- Price
- CLVT $4.85
- RNA $31.12
- Analyst Decision
- CLVT Hold
- RNA Strong Buy
- Analyst Count
- CLVT 6
- RNA 10
- Target Price
- CLVT $7.10
- RNA $65.80
- AVG Volume (30 Days)
- CLVT 7.0M
- RNA 1.3M
- Earning Date
- CLVT 02-19-2025
- RNA 03-07-2025
- Dividend Yield
- CLVT N/A
- RNA N/A
- EPS Growth
- CLVT N/A
- RNA N/A
- EPS
- CLVT N/A
- RNA N/A
- Revenue
- CLVT $2,556,700,000.00
- RNA $10,117,000.00
- Revenue This Year
- CLVT N/A
- RNA N/A
- Revenue Next Year
- CLVT N/A
- RNA N/A
- P/E Ratio
- CLVT N/A
- RNA N/A
- Revenue Growth
- CLVT N/A
- RNA N/A
- 52 Week Low
- CLVT $4.22
- RNA $14.11
- 52 Week High
- CLVT $9.02
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- CLVT 39.29
- RNA 44.06
- Support Level
- CLVT $4.22
- RNA $31.14
- Resistance Level
- CLVT $5.16
- RNA $33.37
- Average True Range (ATR)
- CLVT 0.24
- RNA 1.67
- MACD
- CLVT -0.03
- RNA -0.16
- Stochastic Oscillator
- CLVT 60.00
- RNA 11.27
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.